BioTissue Presents New Data for Cryopreserved Amniotic Membrane Therapy
Findings of a new multicenter, retrospective study conducted on patients with moderate to severe dry eye disease (DED) treated with BioTissue’s self-retained Prokera Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time, according to a BioTissue news release. The research will be presented in a poster at the American Academy of Optometry 2023 meeting this week in New Orleans.
“The findings presented highlight the progress we’ve made in enhancing treatment options for individuals affected by DED, further emphasizing our focus on empowering healthcare professionals to elevate the standards of care and make a positive difference in the lives of their patients,” said BioTissue CEO Ted Davis.
The poster, 'Sutureless Cryopreserved Amniotic Membrane for Moderate to Severe Dry Eye with Short Treatment Duration by Damon Dierker, OD, FAAO, et al.,' re-examines the traditional 5-to-7-day treatment duration for sutureless Cryopreserved Amniotic Membrane in addressing DED. In the study, nine patients were treated with Prokera Slim for just 2 days and were observed at 1-week, 1-month, and 3-month time intervals.
The main result of the study revealed a significant improvement in Dry Eye Workshop (DEWS) scores 1-week, 1-month, and 3-months post-treatment. Baseline scores improved from 3.1 +/- 0.6 at baseline to 1.50 +/- 0.5 at 1-week (P=0.006) and 1.2 +/- 0.4 at both 1- and 3-months (P=0.004) with no reported complications or adverse effects throughout the study. This underscores the significant relief provided by Prokera Slim and the enhancement of clinical signs in DED for a duration of up to 3 months.
“This study has allowed us the opportunity to re-examine the conventional approach to treating moderate to severe DED by significantly decreasing the required treatment duration for patients,” Dr. Dierker said in a company news release. “Administering Prokera Slim for just 2 days and seeing substantial improvements over a 3-month period emphasizes the potential for shorter, more efficient treatments in the future.”
The poster (#59) will be presented on Thursday, October 12, in Exhibit Hall D from 4:30 pm to 6:30 pm.